SCHIZOPHRENIA

This phase 3 trial is testing the long-term safety of an oral drug called HS-10380 in Chinese adults with schizophrenia. Over about a year, 500 participants will take the medication daily, with doses adjusted to an optimal level. The study tracks side effects, serious adverse eve…

This trial tests a medical device that has not yet been approved by the U.S. FDA. The goal is to see if it can help control a specific disease. Participants will use the device as directed, and researchers will monitor its effects on symptoms and disease progression.

This pilot study tests whether combining a gentle brain stimulation technique called tDCS with aerobic exercise can improve cognitive functions like memory and attention in people with schizophrenia. Participants will be randomly assigned to receive either the combined treatment …

This trial is testing a new extended-release injection of brexpiprazole, a medication already used for schizophrenia, to see how it behaves in the body and whether it is safe and tolerable. About 16 adults with schizophrenia will receive a single dose of either 45 mg or 100 mg un…

This trial compares a new long-acting injectable form of the schizophrenia drug cariprazine (called B2227) with the standard oral version, Vraylar. Researchers want to see how the body absorbs and processes each version, and whether the injectable is safe and tolerable. The study…

This early-stage trial is testing a long-acting injectable form of the drug cariprazine, called AX251, in 48 adults with stable schizophrenia. The study aims to see how the drug moves through the body and whether it is safe when given as a single shot at different doses. If resul…

This study tests an experimental drug called VV119 in adults with acute schizophrenia. Participants receive one of three doses of VV119, a placebo, or an active comparator (aripiprazole) for six weeks. The goal is to see if VV119 reduces symptoms like hallucinations and delusions…

This trial investigates whether a gamified eye-movement training program can improve cognitive function in people across different stages of schizophrenia, including those at clinical high risk. Participants will be randomly assigned to either eye-movement training or a finger-co…

This study tests whether a digital platform called mindLAMP can help community health workers in India deliver better care for people with schizophrenia. About 240 adults with schizophrenia and at least one physical health risk (like diabetes or high blood pressure) will take par…

This phase 3 trial tests whether KarXT (a combination of xanomeline and trospium chloride) can prevent relapse in people with schizophrenia. Participants who have had a recent hospitalization for schizophrenia and still have symptoms will receive KarXT or a placebo. The study mea…

This study tests a program that combines executive function training (like planning and problem-solving) with cognitive behavioral social skills training for adults aged 60 and older who have schizophrenia or schizoaffective disorder. Participants attend 42 sessions that teach pr…

This early study tests a new drug called SIPI6398 in 9 people (healthy volunteers and schizophrenia patients). Researchers use brain scans to see how much of the drug reaches brain receptors linked to schizophrenia. The goal is to find the right dose and check safety, not yet to …

This study tests a drug called mirikizumab, which is already approved for other conditions, in people with schizophrenia who have a specific immune marker (AGA IgG antibodies). The goal is to see if it can improve negative symptoms like lack of motivation and pleasure, as well as…

This study tests whether a personalized program of exercise, diet, sleep support, social activities, and a weight-loss drug (semaglutide) can improve mental functioning in 140 adults with depression, bipolar disorder, or schizophrenia. Participants are randomly assigned to the pe…

This study tests whether tracking smartphone activity and offering extra support from peer specialists can help veterans with serious mental illness avoid emergency room visits and hospital stays. About 400 veterans who are at high risk will take part. The goal is to catch early …

This study compares a new injectable form of aripiprazole (SYH9096) to the approved drug Abilify Maintena® in 116 adults with stable schizophrenia. Participants receive five injections of each version, one month apart, to see if the new version reaches similar drug levels in the …

This study looks at whether extra education from a pharmacist can help people aged 18-60 who are starting a new antipsychotic medication for conditions like schizophrenia or bipolar disorder. The goal is to see if this support reduces weight gain and other metabolic side effects.…

This study tests a group psychoeducation program for people with schizophrenia to help them manage relapse and improve functional recovery. Sixty participants will be split into two groups: one receives the program (four 60-minute sessions) and the other does not. Researchers wil…

This study tests whether switching from daily oral antipsychotics to a monthly injection of paliperidone palmitate helps people with schizophrenia control symptoms and improve social function. Researchers will enroll 120 adults aged 18-65 who are stable on oral meds. Participants…

This small pilot study tests whether bromocriptine, a drug used for Parkinson's, can safely improve blood sugar problems in people with schizophrenia who have prediabetes from antipsychotic medications. Fifteen adults will take bromocriptine for 6 weeks, with researchers monitori…

This study will test the safety and effectiveness of paliperidone extended-release tablets in 505 adults with schizophrenia in Bangladesh. Participants will take the medication once daily for 12 weeks, with doses adjusted as needed. Researchers will measure changes in symptoms us…

This study tests whether a non-invasive brain ultrasound, combined with machine learning, can help distinguish people with schizophrenia from healthy individuals. Researchers will scan 200 adults (100 with schizophrenia, 100 without) and measure specific brain features. The goal …

This study will test whether measuring a specific abnormal protein (alpha-synuclein) in spinal fluid can reliably distinguish dementia with Lewy bodies (DLB) from Alzheimer's disease. Researchers will collect samples and perform cognitive tests on 286 older adults with suspected …

This trial tests whether Snoezelen therapy—a calming, multisensory experience using lights, sounds, and textures—can improve health in adults with schizophrenia (including those needing institutional care) and women with alcohol dependence. Participants will attend 30-minute sess…

This study will test a mobile app designed to help people with schizophrenia or those at high risk for psychosis recognize and change biased thinking patterns. One hundred participants will use the app and report on their mood and negative symptoms. The goal is to see if this sim…

This study tests a 12-week online program designed to improve mood and motivation in people with schizophrenia or early psychosis. Participants complete 20-30 minute weekly sessions. Researchers will measure changes in symptoms and goal-directed behavior before and after the prog…

This study tests whether a mobile app that trains specific brain waves can improve working memory in adults with schizophrenia or schizoaffective disorder. Thirty participants will use the app at home twice a week for 12 weeks. Half get real neurofeedback, half get a placebo vers…

This study tests whether 8 weekly group sessions of Acceptance and Commitment Therapy (ACT), led by a nurse, can help people with schizophrenia improve social thinking, emotion control, and mental flexibility. 64 participants will be split into two groups: one gets ACT plus usual…

This study tests whether an 8-session training program based on Acceptance and Commitment Therapy (ACT) can help caregivers of schizophrenia patients feel less burdened, express emotions more healthily, and become more psychologically flexible. About 60 caregivers will be randoml…

This study tests whether gentle ultrasound waves aimed at the brain can help with memory and thinking problems in people with schizophrenia. 140 adults with stable schizophrenia will receive either real or fake ultrasound sessions over 20 days. Researchers will check if memory an…

This study tests a personalized brain stimulation technique called HD-tACS to help people with schizophrenia better combine information from their senses. The treatment is tailored to each patient's brain activity and targets areas involved in sensory binding. The trial will incl…

This study tests whether a non-invasive brain training technique called gamma EEG neurofeedback can improve working memory in adults with schizophrenia or schizoaffective disorder. About 104 participants will be randomly assigned to receive either real neurofeedback (learning to …

This study tests whether a new medicine, Xanomeline/Trospium (also called KarXT), can improve thinking and memory in adults with schizophrenia. Unlike standard antipsychotics, this drug targets a different brain system and may help with cognitive symptoms. Researchers will follow…

This study tests a shared decision-making tool for antipsychotic medications in 120 young adults (ages 18-30) with early psychosis. The goal is to see if the tool helps patients feel more involved in their care and more likely to stick with treatment. Participants will use the de…

This study will test whether an 8-week hatha yoga program is practical and helpful for adults hospitalized with schizophrenia. The goal is to see if yoga can improve mindfulness and how patients recall memories. Thirty-six stable patients will participate in group yoga sessions l…

This study tests whether aerobic exercise, alone or with a gentle brain stimulation technique called tDCS, can improve thinking and memory in people with treatment-resistant schizophrenia. About 160 participants will be assigned to exercise, tDCS plus exercise, or a control group…

This study tests an experimental drug called LY03020 in 160 adults with schizophrenia who are currently having severe symptoms (acute psychosis). Half will get the drug and half a placebo, and neither the patients nor the doctors will know who gets what. The main goal is to see i…

This study tests whether a supplement called pyrroloquinoline quinone (PQQ) can help reduce negative symptoms (like lack of motivation) and improve thinking skills in people with chronic schizophrenia. About 70 adults will receive either PQQ or a placebo for 8 weeks, and research…

This study aims to see if peer support can help pregnant and postpartum veterans who have serious mental illness. Researchers will develop a program where trained peer specialists offer support, then test it with 24 veterans to see if it is helpful and practical. The goal is to i…

This study tests whether adding cannabidiol (CBD) to standard antipsychotic medication can improve symptoms in people experiencing their first episode of psychosis who haven't responded well to initial treatment. About 250 participants aged 16-40 will receive either CBD or a plac…

This study tests whether prucalopride, a drug used for gut issues, can improve thinking and memory in people with schizophrenia. About 34 adults will take the drug for 4 weeks while staying on their usual medications. Researchers will measure changes in memory, attention, and pro…

This study will test if art therapy sessions can lower anxiety and disease severity in 48 adults hospitalized in a psychiatry ward. Participants will be randomly assigned to receive art therapy plus standard care or standard care alone. The goal is to see if creative expression c…

This study is looking for biological markers in the body that might predict how well people with treatment-resistant psychiatric disorders—like schizophrenia, depression, bipolar disorder, OCD, and catatonia—respond to new treatments. Researchers will collect blood, stool, cerebr…

This study uses PET scans to see how two antipsychotic medications, brexpiprazole and cariprazine, bind to dopamine-3 receptors in the brains of people with schizophrenia. Forty participants take one of the drugs for 15 days and get brain scans before, after one day, and after 15…

This study follows 2,000 adults with severe mental illness (such as schizophrenia, bipolar disorder, or severe depression) who are admitted to intensive care units (ICUs) in France. Researchers track their survival and other outcomes for up to 12 months to identify factors that p…

This study will analyze the complete DNA of 1,500 people in Manitoba—some with schizophrenia and some without—to find genetic differences linked to the illness. Researchers will also look at how genes affect medication response and side effects. The goal is to better understand s…

This study will test a new mobile mental health app designed to help people with schizophrenia or schizoaffective disorder stick to their medication routine. Researchers will enroll 50 adults who are in remission and see if using the app is practical and well-liked. The goal is t…

This early-stage study is testing a new drug called KR23248 in 66 healthy adults aged 18 to 45. The main goal is to check if the drug is safe and how the body processes it. Participants will receive either the drug or a placebo. This study does not aim to treat any disease but to…

This pilot study will compare the Clubhouse Model—a structured, community-based program where members work together to run the clubhouse—to standard outpatient care for adults with schizophrenia. Researchers will measure changes in thinking, daily functioning, and brain activity …

This study tests a group program to help veterans with serious mental illness feel more comfortable and confident working with their doctors and therapists. About 119 veterans from three VA centers will take part. The goal is to see if the program improves teamwork between vetera…

This study will follow 120 people with schizophrenia who use cannabis, using mobile phone surveys and thinking tasks to track symptoms in real time. The goal is to understand how cannabis may both worsen positive symptoms (like hallucinations) and reduce negative symptoms (like l…

This early-stage trial will give 8 healthy men a single dose of a radioactive-labeled experimental drug called SEP-380135, which is being developed for schizophrenia. The goal is to track how the drug is absorbed, broken down, and eliminated from the body. This study does not tes…

This research looks at how brain networks relate to thinking and memory problems in people with schizophrenia, bipolar disorder, or major depression. The goal is to use brain imaging to better assess cognitive issues, improve diagnosis, and predict how well treatments might work.…

This study looks at whether teaching people in the hospital about their psychiatric medications helps them stick to their treatment and handle side effects. Researchers will work with 64 adults who have serious mental illnesses like schizophrenia or bipolar disorder. The goal is …

This study investigates how insulin delivered through the nose changes dopamine signaling and energy use in the brains of people with first-episode psychosis. Researchers will compare brain scans and chemical levels in 46 participants (patients and healthy volunteers) after recei…

This study will follow 200 adults in Egypt who have psychosis to compare two conditions: schizophrenia and psychosis caused by methamphetamine use. Researchers will assess symptoms, treatment response, and recovery over three months. The goal is to improve diagnosis and understan…